Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

High levels of immunosuppressant may lead to tumor recurrence

25.04.2005


A new study on the incidence of liver cancer after transplant found that high levels of the immunosuppressant cyclosporine favored tumor recurrence and identified blood levels of the drug that should not be exceeded. Lower levels of cyclosporine levels did not affect rejection rates.

The results of this study appear in the May 2005 issue of Liver Transplantation, the official journal of the American Association for the Study of Liver Diseases (AASLD) and the International Liver Transplantation Society (ILTS). The journal is published on behalf of the societies by John Wiley & Sons, Inc. and is available online via Wiley InterScience at www.interscience.wiley.com/journal/livertransplantation

Hepatocellular carcinoma (HCC, a type of liver cancer) occurs frequently in patients with chronic liver disease who are listed for liver transplants. However, the immunosuppressants necessary to prevent rejection can accelerate tumor growth, and the incidence of tumor recurrence is high.



Because of this, strict selection criteria of patients with HCC has limited their access to transplants, yet the role of immunosuprressants in tumor growth has not been well established. In a previous study, the authors demonstrated a close relationship between the amount of cyclosporine and tumor recurrence in liver transplant patients.

The current study further examines this association and identifies possible strategies to avoid it.

Led by Marco Vivarelli of the department of surgery and transplantation at the University of Bologna, Italy, the study examined 70 patients who took cyclosporine as the main immunosuppressant following liver transplants between 1991 and 2002. The cyclosporine dosage was determined by the clinician in charge based on clinical and biochemical indications, but without regard to blood levels achieved by the drug after it was administered. HCC recurred in 7 of the patients between 2 and 40 months after transplant. The researchers found that the absence of recurrence was significantly related to blood levels of cyclosporine, which were higher in patients whose tumors recurred. Other factors, such as recipient sex, underlying liver disease, or the use of cyclosporine with other immunosuppressants or steroids did not affect tumor recurrence.

"We provide here further evidence on the key role of immunosuppression in tumor recurrence after liver transplantation; in particular, we recommend that in those patients transplanted for hepatocellular carcinoma who receive CsA–based [cyclosporine] immunosuppression the exposure to the drug should not exceed the daily blood levels that we identified," the authors state. Since higher and lower levels of cyclosporine did not affect rejection rates, they suggest that minimum dosage levels of the drug can be safely used. In addition, they suggest that immunosuppressive schedules might be tailored to individual patients based on the biology of their tumors, keeping in mind that high-risk patients would probably benefit from keeping cyclosporine levels as low as possible. They conclude that new immunosuppressant drugs shown to have anti-cancer effects are particularly promising for HCC patients.

David Greenberg | EurekAlert!
Further information:
http://www.wiley.com

More articles from Studies and Analyses:

nachricht The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung

nachricht A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>